|
[1]ZHOU HJ, XIE Q.Strategy for virologic response——guided therapy in integrated diagnosis and treatment of hepatitis C in the era of precision medicine in China[J].J Clin Hepatol, 2016, 32 (7) :1262-1265. (in Chinese) 周惠娟, 谢青.精准医学时代中国丙型肝炎诊疗——一体化的病毒学应答指导治疗策略[J].临床肝胆病杂志, 2016, 32 (7) :1262-1265.
|
|
[2]MOHD HJ, GROEGER AD, FLAXMAN ST.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.
|
|
[3] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.Guidelines of prevention and treatment for hepatitis C[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会, 丙型肝炎防治指南[J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[4]WU D, LI ZW.Accurate clinical examination guarantees the whole management process of hepatitis C patients in the era of direct-acting antiviral agents[J].J Clin Hepatol, 2017, 33 (6) :1058-1062.吴丹, 李智伟.直接抗病毒药物时代精准临床检测在丙型肝炎患者全程管理中的作用[J].临床肝胆病杂志, 2017, 33 (6) :1058-1062.
|
|
[5]ARZUMANYAN A, REIS HM, FEITELSON MA.Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma[J].Nat Rev Cancer, 2013, 13 (2) :123-135.
|
|
[6]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol, 2015, 63 (1) :199-236.
|
|
[7]JACOBSON IM, LIM JK, FRIED MW.American Gastroenterological Association institute clinical practice update-expert review:care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection[J].Gastroenterology, 2017, 152 (6) :1578-1587.
|
|
[8]CARDOSO AC, MOUCARI R, FIGUEIREDO C, et al.Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma:incidence and survival in hepatitis C patients with advanced fibrosis[J].J Hepatol, 2010, 52 (5) :652-657.
|
|
[9]El SERAG HB, KANWAL F, RICHARDSON P, et al.Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection[J].Hepatology, 2016, 64 (1) :130-137.
|
|
[10]CARDOSO H, VALE AM, RODRIGUES S, et al.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis[J].J Hepatol, 2016, 65 (5) :1070-1071.
|
|
[11]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.
|
|
[12]SANGIOVANNI E, DEL P, FASANI C, et al.Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance[J].Gastroenterology, 2004, 126 (4) :1005-1014.
|
|
[13]FATTOVICH G, GIUSTINA G, DEGOS F, et al.Morbidity and mortality in compensated cirrhosis type C:a retrospective followup study of 384 patients[J].Gastroenterology, 1997, 112 (2) :463-472.
|
|
[14]CHEUNG MC, WALKER AJ, HUDSON BE, et al.Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis[J].J Hepatol, 2016, 65 (4) :741-747.
|
|
[15]CALVARUSO V.Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs) [J].Dig Liver Dis, 2017, 49 (1) :e60.
|
|
[16]KOBAYASHI M, SUZUKI F, FUJIYAMA S, et al.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection[J].J Med Virol, 2017, 89 (3) :476-483.
|
|
[17]HASSON H.Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals[J].J Hepatol, 2017, 67 (2) :415-417.
|
|
[18]REIG M, MARINO Z, PERELLO M, et al.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J].J Hepatol, 2016, 65 (4) :719-726.
|
|
[19]ZAMPARELLI MS.Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents.A single center experience[J].Dig Liver Dis, 2017, 49 (1) :e45-e46.
|
|
[20]YANG JD, AQEL BA, PUNGPAPONG S, et al.Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma[J].J Hepatol, 2016, 65 (4) :859-860.
|
|
[21]TORRES HA, VAUTHEY JN, ECONOMIDES MP, et al.Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals:first, do no harm by withdrawing treatment[J].J Hepatol, 2016, 65 (4) :862-864.
|
|
[22]ZAVAGLIA C, OKOLICSANYI S, CESRINI L, et al.Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?[J].J Hepatol, 2017, 66 (1) :236-237.
|
|
[23]CABIBBO G.Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs) [J].Dig Liver Dis, 2017, 49 (1) :e59.
|
|
[24]The ANRS collaborative study group on hepatocellular carcinoma.Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma:data from three ANRS cohorts[J].J Hepatol, 2016, 65 (4) :734-740.
|
|
[25]PETTA G, CABIBBO M, BARBARA S, et al.Hepatocellular carcinoma recurrence in patients with curative resection or ablation:impact of HCV eradication does not depend on the use of interferon[J].Aliment Pharmacol Ther, 2017, 45 (1) :160-168.
|
|
[26]IRSHADM M, MANKOTIA DS, IRSHAD K.An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J].World J Gastroenterol, 2013, 19 (44) :7896-7909.
|
|
[27]KOZBIAL S, MOSER R, SCHWARER H, et al.Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment[J].J Hepatol, 2016, 65 (4) :856-858.
|
DownLoad: